ArticleJournal of the American Academy of Dermatology2014
A population-based study of the association between bullous pemphigoid and neurologic disorders.
Article in Journal of the American Academy of Dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 5 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Interventions for bullous pemphigoid.The Cochrane database of systematic reviews · 2023Pooled it
- Pooled it
- The association between Parkinson's disease and autoimmune diseases: A systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis.JAMA dermatology · 2020Pooled it
- Dystonin/BPAG1 modulates diabetes and Alzheimer's disease cross-talk: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019Pooled it
- Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.Lancet (London, England) · 2017Trial
- Serum BP180 and BP230 autoantibodies in Alzheimer's disease: diagnostic and cognitive associations in a retrospective study.Frontiers in aging neuroscience · 2026Article
- From Skin to Brain: Key Genetic Mediators Associating Cutaneous Inflammation and Neurodegenerative Diseases.Genes · 2025Review
- Association of statins, gliptins, and antipsychotics with bullous pemphigoid: A case-control study in the Cretan population.The Journal of dermatology · 2025Article
- Chronic disease associated with bullous pemphigoid risk: A systematic review and meta-analysis.JAAD international · 2024Article
- Factors Influencing the Clinical Course of Bullous Pemphigoid among Geriatric Patients: A Pilot Study.Medicina (Kaunas, Lithuania) · 2024Article
- Systemic Implications of Bullous Pemphigoid: Bridging Dermatology and Internal Medicine.Diagnostics (Basel, Switzerland) · 2024Review
- Bullous pemphigoid and its association with neurological diseases.Journal of the colleges of medicine of South Africa · 2024Article
- The effect of dipeptidyl peptidase-4 inhibitor on incidence and clinical course in bullous pemphigoid patients in a tertiary medical center.The Kaohsiung journal of medical sciences · 2023Article
- Autoimmune encephalitis associated with autoimmune blistering diseases: A case series and retrospective review.JAAD case reports · 2023Article
- Comorbidities in Patients with Autoimmune Bullous Disorders: Hospital-Based Registry Study.Life (Basel, Switzerland) · 2022Article
- Bullous pemphigoid: An immune disorder related to aging (Review).Experimental and therapeutic medicine · 2022Review
- Type XVII collagen: Relevance of distinct epitopes, complement-independent effects, and association with neurological disorders in pemphigoid disorders.Frontiers in immunology · 2022Review
- Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients' Assessment.Clinical, cosmetic and investigational dermatology · 2022Review
- IL-13 Genetic Susceptibility to Bullous Pemphigoid: A Potential Target for Treatment and a Prognostic Marker.Frontiers in immunology · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundBullous pemphigoid (BP) has been associated with neurologic disorders.
objectiveWe sought to analyze the association between BP and neurologic disorders.
methodsWe retrospectively identified residents of Olmsted County, Minnesota, with a first lifetime diagnosis of BP between January 1, 1960, and December 31, 2009. Three age- and sex-matched Olmsted County, Minnesota, residents without BP were selected as control subjects for each patient. We compared history of or development of neurologic disorders (dementia, Alzheimer disease, Parkinson disease, multiple sclerosis, cerebrovascular disease, and seizures) between groups using case-control and cohort designs.
resultsIn all, 87 patients with BP were identified and matched to 261 control subjects. The odds of a previous diagnosis of any neurologic disorder or a history of dementia were significantly increased among cases compared with controls (odds ratio 6.85; 95% confidence interval [CI] 3.00-15.64; P < .001; and odds ratio 6.75; 95% CI 2.08-21.92; P = .002, respectively). Both Parkinson disease (hazard ratio 8.56; 95% CI 1.55-47.25; P = .01) and any type of neurologic disorder (hazard ratio 2.02; 95% CI 1.17-3.49; P = .01) were significantly more likely to develop during follow-up in patients with than without BP. LIMITATIONS: Small geographic area and retrospective study design are limitations.
conclusionFindings confirmed an association of BP with neurologic disorders, especially dementia and Parkinson disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.